Jaguar Health, Inc. (NASDAQ:JAGX)

BRIEF

published on 01/22/2026 at 15:05, 10 days 4 hours ago

Jaguar Health Advances Crofelemer for Intestinal Failure Diseases

Crofelemer FDA Approval Jaguar Health Rare Diseases Intestinal Failure
PRESS RELEASE

published on 01/22/2026 at 15:00, 10 days 4 hours ago

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
Jaguar Health, Inc. provides updates on rare disease program for crofelemer, focusing on intestinal failure treatment milestones, Orphan Drug Designation, and global development efforts

Crofelemer Jaguar Health Orphan Drug Designation Rare Disease Intestinal Failure
BRIEF

published on 01/14/2026 at 15:05, 18 days 4 hours ago

Jaguar Health to Present at Lytham Partners Healthcare Summit

Crofelemer Virtual Presentation Jaguar Health Healthcare Summit Gastrointestinal Medicines
PRESS RELEASE

published on 01/14/2026 at 15:00, 18 days 4 hours ago

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
Jaguar Health announces virtual presentation by CEO Lisa Conte at Lytham Partners Healthcare Investor Summit. Company focuses on developing plant-based medicines for gastrointestinal distress

Gastrointestinal Distress Virtual Presentation Jaguar Health Lisa Conte Plant-based Medicines
BRIEF

published on 01/12/2026 at 15:05, 20 days 4 hours ago

Jaguar Health Secures U.S. License Deal with Future Pak for Crofelemer

Crofelemer Jaguar Health Future Pak U.S. License Agreement Rare-disease Pipeline
PRESS RELEASE

published on 01/12/2026 at 15:00, 20 days 4 hours ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
Jaguar Health, Inc. enters U.S. licensing agreement with Future Pak, LLC for exclusive marketing rights of Mytesi® and Canalevia®-CA1, securing $18M upfront payment and potential $20M in milestone payments

Licensing Agreement Jaguar Health Canalevia-CA1 Mytesi Future Pak
BRIEF

published on 01/06/2026 at 15:05, 26 days 4 hours ago

Jaguar Health's Crofelemer Shows Promise in Intestinal Failure Treatment

Crofelemer Jaguar Health Intestinal Failure Parenteral Support Pediatric Study
PRESS RELEASE

published on 01/06/2026 at 15:00, 26 days 4 hours ago

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Jaguar Health announced groundbreaking results from ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure, showing significant reduction of parenteral support (PS) and potential to save lives

Crofelemer Jaguar Health Pediatric Patients Intestinal Failure Parenteral Support
BRIEF

published on 01/02/2026 at 15:05, 30 days 4 hours ago

Jaguar Health Secures FDA Grant for Canalevia-CA1 Studies

Veterinary Medicine Jaguar Health Canalevia-CA1 Dog Diarrhea Treatment FDA Grant
PRESS RELEASE

published on 01/02/2026 at 15:00, 30 days 4 hours ago

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. receives $240,000 grant from FDA for Canalevia-CA1 study on chemotherapy-induced diarrhea in dogs. Focus on CID treatment effectiveness

Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea Grant Dogs

Published on 01/31/2026 at 03:15, 1 day 16 hours ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 1 day 17 hours ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 1 day 18 hours ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 1 day 19 hours ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 1 day 20 hours ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 15:54, 1 day 3 hours ago

EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 1 day 7 hours ago

JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 17 hours ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 21 hours ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 23 hours ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026

View all EQS

Published on 01/30/2026 at 17:45, 2 days 2 hours ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 2 days 11 hours ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 3 days 1 hour ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 3 days 2 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 3 days 2 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News